<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966209</url>
  </required_header>
  <id_info>
    <org_study_id>JS001LT</org_study_id>
    <nct_id>NCT03966209</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant</brief_title>
  <official_title>Evaluation of PD-1 Inhibition in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a perspective clinical study to assess the safety and efficacy of PD-1 inhibitors in
      patients with LT. Eligible patients have recurrent or metastatic cancer after LT, are not
      amenable to, or refractory after, locoregional therapy or to a curative treatment approach
      (eg, surgery, or ablation) and have previously been treated with sorafenib or other targeted
      therapy, either intolerant to this treatment or show radiographic progression after
      treatment.

      Biopsy is needed to exclude patients with positive allograft PD-L1 expression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Event Rate</measure>
    <time_frame>1.5 years</time_frame>
    <description>the occurrence rate of serious adverse event after PD-1 inhibitor treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Graft Rejection Rate</measure>
    <time_frame>1.5 years</time_frame>
    <description>the occurrence rate of acute graft rejection after PD-1 inhibitor treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Objective Response Rate after PD-1 inhibitor treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate</measure>
    <time_frame>3 years</time_frame>
    <description>survival time after PD-1 inhibitor treatment till tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over all survival Rate</measure>
    <time_frame>3 years</time_frame>
    <description>survival time after PD-1 inhibitor treatment till patient death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JS001（PD-1 inhibitor）, 240mg I.V. Q3W,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS001(PD-1 inhibitor)</intervention_name>
    <description>240mg I.V. Q3W</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with recurrence or metastases Hepatocellular carcinoma after liver
             transplantation that not suitable for surgical resection and Local treatments such as
             radiofrequency ablation, transcatheter arterial embolization and radiotherapy, been
             treated with sorafenib or other targeted therapy and are either intolerant to this
             treatment or show radiographic progression after treatment.

          2. Age 18-70 years old, male or female

          3. Biopsy shows negative allograft PD-L1 expression

          4. Child-Pugh score ≤ 6 points (Child-Pugh A)

          5. Estimated postoperative survival time ≥ 12 weeks

          6. ECOG score 0-1 points

          7. Laboratory test indicators: white blood cells ≥ 3.0 × 109 / L, platelets ≥ 80 × 109 /
             L, hemoglobin ≥ 100g / L; total bilirubin ≤ 2.5 times the upper limit of normal,
             transaminase (AST, ALT) ≤ 2.5 times Upper limit of normal value, serum creatinine ≤
             1.5 times normal upper limit

          8. Have sufficient understanding and voluntarily sign informed consent to participate in
             clinical research

        Exclusion Criteria:

          1. Biopsy shows positive allograft PD-L1 expression

          2. Severe allergic reactions to other monoclonal antibodies

          3. Have any history of active autoimmune diseases or autoimmune diseases

          4. The presence of active infection with Hepatitis B or Hepatitis C Virus

          5. Severe cardiopulmonary dysfunction patients, have high blood pressure and blood
             pressure can not be controlled with drugs, unstable coronary artery disease
             (uncontrollable arrhythmia, unstable angina), non-compensatory congestive heart
             failure, within 6 months Myocardial infarction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaowu Huang, M.D.</last_name>
    <phone>+86-13701811021</phone>
    <email>huang.xiaowu@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangyu Wang</last_name>
      <phone>+86-21-64041990</phone>
      <phone_ext>2220</phone_ext>
      <email>wang.xiangyu@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Jian Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Checkpoint Inhibitor</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

